# Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
Canonical URL: https://biopharmsignal.com/news/APRE/aprea-therapeutics-strengthens-global-patent-portfolio-in-dna-damage-response-ddr-cancer-therapeutics-paving-way-for-pipeline-growth
Ticker: APRE
Company: Aprea Therapeutics
Source: Aprea Therapeutics
Published: 2026-02-12 13:30 EST
Original Source URL: https://ir.aprea.com
## Summary

New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea’s WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045. Lead WEE1 inhibitor candidate APR-1051 is advancing in Phase 1 trials, with early clinical proof of concept

## Article Body
New patents granted in 2025 in Australia and Japan bolster global IP coverage for Aprea’s WEE1 and ATR programs. Core patent families are expected to provide exclusivity into 2045. Lead WEE1 inhibitor candidate APR-1051 is advancing in Phase 1 trials, with early clinical proof of concept
## Recent Company News
- 2026-06-01 12:00 EST — [Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors](https://biopharmsignal.com/news/APRE/aprea-therapeutics-presents-updated-phase-1-data-on-wee1-inhibitor-apr-1051-at-asco-2026-demonstrating-early-monotherapy-activity-and-manageable-tolerability-in-advanced-solid-tumors) — Source: Aprea Therapeutics
- 2026-05-13 10:30 EST — [Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update](https://biopharmsignal.com/news/APRE/aprea-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update) — Source: Aprea Therapeutics
- 2026-04-21 14:15 EST — [Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting](https://biopharmsignal.com/news/APRE/aprea-therapeutics-to-provide-clinical-update-on-acesot-1051-phase-1-trial-evaluating-wee1-inhibitor-apr-1051-at-asco-2026-annual-meeting) — Source: Aprea Therapeutics
- 2026-04-01 12:31 EST — [Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement](https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-closing-of-oversubscribed-30-million-private-placement) — Source: Aprea Therapeutics
- 2026-03-30 12:01 EST — [Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement](https://biopharmsignal.com/news/APRE/aprea-therapeutics-announces-oversubscribed-30-million-private-placement) — Source: Aprea Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)